Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
NURO's Cash to Debt is ranked higher than
86% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. NURO: No Debt )
NURO' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: No Debt

Equity to Asset 0.50
NURO's Equity to Asset is ranked higher than
61% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NURO: 0.50 )
NURO' s 10-Year Equity to Asset Range
Min: -6.3   Max: 0.91
Current: 0.5

-6.3
0.91
Interest Coverage No Debt
NURO's Interest Coverage is ranked higher than
85% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. NURO: No Debt )
NURO' s 10-Year Interest Coverage Range
Min: 68   Max: 9999.99
Current: No Debt

68
9999.99
F-Score: 4
Z-Score: -12.88
M-Score: -3.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -139.40
NURO's Operating margin (%) is ranked lower than
52% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. NURO: -139.40 )
NURO' s 10-Year Operating margin (%) Range
Min: -261.35   Max: 5.18
Current: -139.4

-261.35
5.18
Net-margin (%) -151.90
NURO's Net-margin (%) is ranked lower than
51% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.98 vs. NURO: -151.90 )
NURO' s 10-Year Net-margin (%) Range
Min: -251.65   Max: 7.72
Current: -151.9

-251.65
7.72
ROE (%) -111.45
NURO's ROE (%) is ranked lower than
51% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. NURO: -111.45 )
NURO' s 10-Year ROE (%) Range
Min: -121.45   Max: 9.83
Current: -111.45

-121.45
9.83
ROA (%) -74.27
NURO's ROA (%) is ranked lower than
52% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. NURO: -74.27 )
NURO' s 10-Year ROA (%) Range
Min: -92.01   Max: 7.66
Current: -74.27

-92.01
7.66
ROC (Joel Greenblatt) (%) -3213.54
NURO's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. NURO: -3213.54 )
NURO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3408.84   Max: 106.43
Current: -3213.54

-3408.84
106.43
Revenue Growth (%) -56.10
NURO's Revenue Growth (%) is ranked lower than
51% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. NURO: -56.10 )
NURO' s 10-Year Revenue Growth (%) Range
Min: -58.7   Max: 4.3
Current: -56.1

-58.7
4.3
EBITDA Growth (%) -54.20
NURO's EBITDA Growth (%) is ranked lower than
51% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.40 vs. NURO: -54.20 )
NURO' s 10-Year EBITDA Growth (%) Range
Min: -59.9   Max: 10.1
Current: -54.2

-59.9
10.1
EPS Growth (%) -52.70
NURO's EPS Growth (%) is ranked lower than
51% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. NURO: -52.70 )
NURO' s 10-Year EPS Growth (%) Range
Min: -52.7   Max: 3.4
Current: -52.7

-52.7
3.4
» NURO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

NURO Guru Trades in Q2 2013

Jim Simons 91,325 sh (+8.3%)
» More
Q3 2013

NURO Guru Trades in Q3 2013

Jim Simons 87,925 sh (-3.72%)
» More
Q4 2013

NURO Guru Trades in Q4 2013

Jim Simons 78,950 sh (-10.21%)
» More
Q1 2014

NURO Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NURO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
NURO's P/B is ranked higher than
85% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. NURO: 1.60 )
NURO' s 10-Year P/B Range
Min: 0.27   Max: 13.18
Current: 1.6

0.27
13.18
P/S 1.60
NURO's P/S is ranked higher than
79% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. NURO: 1.60 )
NURO' s 10-Year P/S Range
Min: 0.2   Max: 15.14
Current: 1.6

0.2
15.14
EV-to-EBIT -0.13
NURO's EV-to-EBIT is ranked higher than
62% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. NURO: -0.13 )
NURO' s 10-Year EV-to-EBIT Range
Min: 38   Max: 3223.1
Current: -0.13

38
3223.1
Current Ratio 6.40
NURO's Current Ratio is ranked higher than
91% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. NURO: 6.40 )
NURO' s 10-Year Current Ratio Range
Min: 2.29   Max: 13.01
Current: 6.4

2.29
13.01
Quick Ratio 6.14
NURO's Quick Ratio is ranked higher than
93% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. NURO: 6.14 )
NURO' s 10-Year Quick Ratio Range
Min: 1.79   Max: 12.52
Current: 6.14

1.79
12.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
NURO's Price/Net Cash is ranked higher than
98% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NURO: 2.00 )
NURO' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 19.26
Current: 2

0.68
19.26
Price/Net Current Asset Value 1.80
NURO's Price/Net Current Asset Value is ranked higher than
98% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. NURO: 1.80 )
NURO' s 10-Year Price/Net Current Asset Value Range
Min: 0.56   Max: 15.74
Current: 1.8

0.56
15.74
Price/Tangible Book 1.60
NURO's Price/Tangible Book is ranked higher than
92% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.39 vs. NURO: 1.60 )
NURO' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 13.02
Current: 1.6

0.44
13.02
Price/Median PS Value 1.40
NURO's Price/Median PS Value is ranked higher than
65% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. NURO: 1.40 )
NURO' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 12.54
Current: 1.4

0.34
12.54
Earnings Yield (Greenblatt) 2360.50
NURO's Earnings Yield (Greenblatt) is ranked higher than
99% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. NURO: 2360.50 )
NURO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 2360.5
Current: 2360.5

0.2
2360.5
Forward Rate of Return (Yacktman) -605.08
NURO's Forward Rate of Return (Yacktman) is ranked lower than
52% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. NURO: -605.08 )
NURO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20.8   Max: 46
Current: -605.08

-20.8
46

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:NLZB.Germany
NeuroMetrix, Inc was incorporated in Delaware in June 1996. The Company is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company develops and markets neurodiagnostic systems which typically consist of a medical device plus single-use biosensors or electrodes. Other accessories are also offered to its customers. Its initial product for diabetic neuropathy, NC-stat DPNCheck, was launched in September 2011. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as DPN. It is designed to be used by primary care physicians, endocrinologists, podiatrists and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN. The Company also markets a medical device, which has been cleared by the FDA and which is used for the assessment of neuropathies such as carpal tunnel syndrome, diabetes, and sciatica. Its ADVANCE NCS/EMG System, or the ADVANCE System, which is a part of its legacy neurodiagnostics business, is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Its ADVANCE System is comprised of: (1) various types of electrodes and needles, (2) its ADVANCE device and related modules, and (3) a communication hub that enables the physician's office to network their device to its servers for data archiving, report generation and other network services. The Company competes with CareFusion Corporation, Cadwell Laboratories, Inc., and Natus Medical Incorporated. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the regulations promulgated thereunder, as well as by other regulatory bodies in the United States and abroad.
» More Articles for NURO

Headlines

Articles On GuruFocus.com
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 200,000 Shares Nov 18 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Nov 09 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Aug 10 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) May 14 2010 
NeuroMetrix, Inc. Announces Second Quarter 2009 Financial Results Aug 05 2009 
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 100,000 Shares Mar 03 2009 
NeuroMetrix, Inc. Reports Total Revenues of $7.2 Million for the Fourth Quarter of 2008 Feb 10 2009 
Nucor Invites You to Join Its Fourth Quarter and Year End of 2008 Conference Call on the Web Jan 02 2009 
Nucor Announces One-Hundred Forty-Third (143rd) Consecutive Cash Dividend Dec 09 2008 

More From Other Websites
Bacterin Announces the Appointment of New Board Member Aug 13 2014
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights Jul 24 2014
Q2 2014 NeuroMetrix Inc. Earnings Release - Before Market Open Jul 24 2014
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights Jul 24 2014
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ Jul 22 2014
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ Jul 22 2014
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call Jul 17 2014
NeuroMetrix's OTC Pain Management Device Gets FDA Nod, Shares Up Jul 10 2014
Why NeuroMetrix (NURO) Stock Is Soaring Today Jul 08 2014
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain Jul 08 2014
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain Jul 08 2014
NeuroMetrix Announces $8 Million Preferred Stock Placement Jun 24 2014
Why NeuroMetrix (NURO) Stock Is Surging Today Jun 24 2014
NeuroMetrix Reports Japan Regulatory Approval for NC-stat DPNCheck Jun 24 2014
NeuroMetrix Reports Japan Regulatory Approval for NC-stat DPNCheck Jun 24 2014
Conatus Pharmaceuticals (CNAT) Crumbles: Stock Plunges by 18.7% Jun 13 2014
Strength Seen in Conatus Pharmaceuticals (CNAT): Stock Soars 56.7% Jun 12 2014
NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in China Jun 10 2014
NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in China Jun 10 2014
NeuroMetrix to Exhibit at American Diabetes Association’s 74th Scientific Sessions Jun 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK